RT Journal Article
SR Electronic
T1 A comprehensive analysis of outcomes between COVID-19 patients with an elevated serum lipase compared to those with pancreatitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.13.21252871
DO 10.1101/2021.04.13.21252871
A1 Benias, Petros C
A1 Inamdar, Sumant
A1 Wee, Diana
A1 Liu, Yan
A1 Buscaglia, Jonathan M
A1 Satapathy, Sanjaya K
A1 Trindade, Arvind J
A1 Northwell COVID-19 Research Consortium.
YR 2021
UL http://medrxiv.org/content/early/2021/04/14/2021.04.13.21252871.abstract
AB Background and Aims COVID-19 patients may have asymptomatic hyperlipasemia without abdominal imaging findings or abdominal pain. In addition, primary and secondary pancreatitis have been described in COVID-19 patients. There is limited information on how the groups compare in outcomes. The aim is to compare outcomes among these groups.Methods This is a retrospective study from 12 hospitals within one healthcare system examining outcomes between hospitalized COVID-19 patients with a lipase <3x upper limit of normal (ULN), asymptomatic hyperlipasemia (>3x ULN), secondary pancreatitis (typical respiratory COVID-19 symptoms and found to have pancreatitis), and primary pancreatitis (presenting with pancreatitis).Results Of 11,883 patients admitted with COVID-19, 1,560 patients were included: 1,155 COVID-19 patients with a normal serum lipase (control group), 270 with an elevated lipase <3x ULN, 46 patients with asymptomatic hyperlipasemia with a lipase 3xULN, 57 patients with secondary pancreatitis, and 32 patients with primary pancreatitis. On adjusted multivariate analysis, the elevated lipase <3x ULN and asymptomatic hyperlipasemia groups had worse outcomes. The mortality was OR1.6 (95% CI 1.2-2.2) and 1.1 (95% CI 0.5-2.3), respectively. The need for mechanical ventilation was OR 2.8 (95% CI 1.2-2.1) and 2.8 (95% CI 1.5-5.2), respectively. Longer length of stay was OR 1.5 (95%CI 1.1-2.0) and 3.16 (95%CI 1.5-6.5), respectively.Conclusion COVID-19 patients with an elevated lipase< 3x ULN and asymptomatic hyperlipasemia have generally worse outcomes than those with pancreatitis. This could be attributed to extrapancreatic causes (liver failure, renal failure, enteritis, etc), which may signify a more severe course of clinical disease.Competing Interest StatementPCB: Consultant for Olympus America, Apollo Medical, FujiFilm, and Boston Scientific JB: Consultant and speaker for Abbvie Inc. AJT: Consultant for Olympus America and Pentax Medical Research Support form Ninepoint Medical Funding StatementThis project was unfunded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approval (IRB #20-0200, Registry of patients who are presenting under the suspicion of COVID-19) was obtained for this study by the Northwell Health Feinstein Institute for Medical Research, Office of the Human Research Protection Program (Hallie Kassan, MD; Director)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request